Stockscreener 앱 받기
26.05
1.40%
0.36
시간 외 거래:
26.05
전일 마감가:
$25.69
열려 있는:
$25.95
하루 거래량:
493.60K
Relative Volume:
0.62
시가총액:
$1.55B
수익:
-
순이익/손실:
$-131.11M
주가수익비율:
-11.98
EPS:
-2.1745
순현금흐름:
$-102.47M
1주 성능:
+3.01%
1개월 성능:
-18.21%
6개월 성능:
-17.51%
1년 성능:
+122.65%
1일 변동 폭
$25.95
$26.81
1주일 범위
$24.98
$27.05
52주 변동 폭
$11.60
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
명칭
Tyra Biosciences Inc
전화
(619) 728-4760
주소
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
26.05 | 1.53B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Guggenheim | Buy |
| 2026-04-06 | 개시 | Canaccord Genuity | Buy |
| 2026-02-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-02-10 | 개시 | William Blair | Outperform |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-21 | 재개 | Piper Sandler | Overweight |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-10-18 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-08-15 | 개시 | Piper Sandler | Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-30 | 개시 | Wedbush | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-06-23 | 개시 | H.C. Wainwright | Buy |
| 2022-03-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-10-11 | 개시 | BofA Securities | Buy |
| 2021-10-11 | 개시 | Cowen | Outperform |
| 2021-10-11 | 개시 | Jefferies | Buy |
모두보기
Tyra Biosciences Inc 주식(TYRA)의 최신 뉴스
Tyra’s one-drug, three-indication bet nears its first phase 2 test - Pharma Voice
Farallon Capital Management Slashes Tyra Biosciences (TYRA) Stak - GuruFocus
Tyra Biosciences Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Tyra Biosciences tests innovative therapy in SURF302 for intermediate-risk bladder cancer - Traders Union
Tyra Biosciences (NASDAQ: TYRA): What Comes Next for Its Pipeline? - Kalkine Media
Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2%Time to Buy? - MarketBeat
TYRA Q2 2026 Earnings: EPS Miss Slightly Overshadowed by 6.98% Share AdvanceBasic EPS Analysis - vinanet.vn
TYRA Q2 2026 Earnings: EPS Misses Estimates by 4.14% as Shares Gain 1.08%Healthcare Earnings Report - vinanet.vn
TYRA Q2 2026 Earnings: Wider-than-Expected Loss of -$0.69 per Share, Yet Stock Rises 1.08%Dividend Growth Analysis - vinanet.vn
Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA - MarketBeat
TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake - Stock Titan
Tyra Biosciences examines FGFR3 gene impact on cell growth disorders - Traders Union
Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake - Stock Titan
Avoiding Lag: Real-Time Signals in (TYRA) Movement - Stock Traders Daily
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside - TradingView
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
BofA Adjusts Price Target on Tyra Bioscience to $39 From $42 - marketscreener.com
TYRA's dabogratinib trial in 2026 could validat... - Pluang
Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet (NASDAQ:TYRA) - Seeking Alpha
HC Wainwright Brokers Lower Earnings Estimates for TYRA - MarketBeat
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TYRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Pipeline InvestmentFinancial Health Score - vinanet.vn
Tyra Biosciences (TYRA) Projected to Announce Earnings on Thursday - MarketBeat
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BlackRock, Inc. Expands Tyra Biosciences (TYRA) Stake with Strat - GuruFocus
Jefferies Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - Moomoo
TYRA Shares Drop Amid Market Volatility; Price-to-Sales Highligh - GuruFocus
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down Following Weak Earnings - marketbeat.com
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - Moomoo
Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Tyra Biosciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Tyra Biosciences 2Q 2026: Net loss $45.6M, EPS $(0.69) — 10-Q Summary - TradingView
Tyra Biosciences Q2 net loss widens on higher R&D expenses - TradingView
Tyra Biosciences posts Q2 2026 net loss $45.6M; cash $353.9M, runway into 2H 2028 - TradingView
TYRA: Phase 2 trials progress, strong cash runway, and higher R&D drive increased net loss - TradingView
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights - PR Newswire
Arkadios Wealth Advisors Makes New $1.82 Million Investment in Tyra Biosciences, Inc. $TYRA - MarketBeat
Tyra Biosciences (TYRA) Edges Up to $32.15 as Biotech Sentiment SteadiesWMA Signal - dars.gov.et
Discipline and Rules-Based Execution in TYRA Response - Stock Traders Daily
Tyra Biosciences, Inc. $TYRA Stock Position Boosted by Seven Fleet Capital Management LP - MarketBeat
TYRA Q1 2026 Earnings: EPS Falls Short of Estimates as Clinical Pipeline Investment DeepensEarnings Miss Streak - vinanet.vn
Janus Henderson Group PLC Acquires 955,147 Shares of Tyra Biosciences, Inc. $TYRA - MarketBeat
TYRA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial - TipRanks
TYRA Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Advances PipelineEstimate Revision Count - vinanet.vn
Tyra Biosciences, Inc. $TYRA Shares Sold by Eversept Partners LP - MarketBeat
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tyra Biosciences Inc (TYRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.07%
자본화:
|
볼륨(24시간):